Widespread white matter microstructural abnormalities in bipolar disorder: evidence from mega- and meta-analyses across 3033 individuals
Carregando...
Citações na Scopus
133
Tipo de produção
article
Data de publicação
2019
Editora
NATURE PUBLISHING GROUP
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
FAVRE, Pauline
PAULING, Melissa
STOUT, Jacques
HOZER, Franz
SARRAZIN, Samuel
ABE, Christoph
ALDA, Martin
ALLOZA, Clara
ALONSO-LANA, Silvia
ANDREASSEN, Ole A.
Autor de Grupo de pesquisa
ENIGMA Bipolar Disorder Working
Editores
Coordenadores
Organizadores
Citação
NEUROPSYCHOPHARMACOLOGY, v.44, n.13, p.2285-2293, 2019
Resumo
Fronto-limbic white matter (WM) abnormalities are assumed to lie at the heart of the pathophysiology of bipolar disorder (BD); however, diffusion tensor imaging (DTI) studies have reported heterogeneous results and it is not clear how the clinical heterogeneity is related to the observed differences. This study aimed to identify WM abnormalities that differentiate patients with BD from healthy controls (HC) in the largest DTI dataset of patients with BD to date, collected via the ENIGMA network. We gathered individual tensor-derived regional metrics from 26 cohorts leading to a sample size of N = 3033 (1482 BD and 1551 HC). Mean fractional anisotropy (FA) from 43 regions of interest (ROI) and average whole-brain FA were entered into univariate mega- and meta-analyses to differentiate patients with BD from HC. Mega-analysis revealed significantly lower FA in patients with BD compared with HC in 29 regions, with the highest effect sizes observed within the corpus callosum (R-2 = 0.041, P-corr < 0.001) and cingulum (right: R-2 = 0.041, left: R-2 = 0.040, P-corr < 0.001). Lithium medication, later onset and short disease duration were related to higher FA along multiple ROIs. Results of the meta-analysis showed similar effects. We demonstrated widespread WM abnormalities in BD and highlighted that altered WM connectivity within the corpus callosum and the cingulum are strongly associated with BD. These brain abnormalities could represent a biomarker for use in the diagnosis of BD. Interactive three-dimensional visualization of the results is available at www.enigma-viewer.org.
Palavras-chave
Referências
- Abramovic L, 2018, EUR NEUROPSYCHOPHARM, V28, P743, DOI 10.1016/j.euroneuro.2018.01.001
- Anderson LB, 2017, ARCH CLIN NEUROPSYCH, V32, P267, DOI 10.1093/arclin/acx001
- BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1
- Bates D, 2013, J STAT SOFTW, V52, P1
- Benedetti F, 2013, NEUROPSYCHOPHARMACOL, V38, P313, DOI 10.1038/npp.2012.172
- Cui LQ, 2011, PSYCHIAT RES-NEUROIM, V194, P347, DOI 10.1016/j.pscychresns.2011.03.010
- Favre P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134961
- Favre P, 2014, J AFFECT DISORDERS, V165, P182, DOI 10.1016/j.jad.2014.04.054
- Goldberg JF, 2002, J CLIN PSYCHIAT, V63, P985, DOI 10.4088/JCP.v63n1105
- Ha TH, 2011, NEUROSCI LETT, V505, P150, DOI 10.1016/j.neulet.2011.10.009
- Hajek T, 2012, J PSYCHIATR NEUROSCI, V37, P185, DOI 10.1503/jpn.110097
- Hibar DP, 2018, MOL PSYCHIATR, V23, P932, DOI 10.1038/mp.2017.73
- Hibar DP, 2016, MOL PSYCHIATR, V21, P1710, DOI 10.1038/mp.2015.227
- Houenou J, 2007, MOL PSYCHIATR, V12, P1001, DOI 10.1038/sj.mp.4002010
- Ji E, 2019, SCHIZOPHRENIA BULL, V45, P1367, DOI 10.1093/schbul/sbz015
- Kelly S, 2018, MOL PSYCHIATR, V23, P1261, DOI 10.1038/mp.2017.170
- Kochunov P, 2014, NEUROIMAGE, V95, P136, DOI 10.1016/j.neuroimage.2014.03.033
- Leow A, 2013, BIOL PSYCHIAT, V73, P183, DOI 10.1016/j.biopsych.2012.09.014
- Linke J, 2013, BIOL PSYCHIAT, V74, P908, DOI 10.1016/j.biopsych.2013.04.010
- Lyoo IK, 2010, NEUROPSYCHOPHARMACOL, V35, P1743, DOI 10.1038/npp.2010.41
- Mahon K, 2010, NEUROSCI BIOBEHAV R, V34, P533, DOI 10.1016/j.neubiorev.2009.10.012
- Marlinge E, 2014, BIPOLAR DISORD, V16, P97, DOI 10.1111/bdi.12135
- Meffre D, 2015, NEUROSCIENCE, V284, P962, DOI 10.1016/j.neuroscience.2014.10.064
- Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543
- Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40
- Moore GJ, 2009, J CLIN PSYCHIAT, V70, P699, DOI 10.4088/JCP.07m03745
- Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035
- Nortje G, 2013, J AFFECT DISORDERS, V150, P192, DOI 10.1016/j.jad.2013.05.034
- Phillips ML, 2014, AM J PSYCHIAT, V171, P829, DOI 10.1176/appi.ajp.2014.13081008
- Repple J, 2017, BIPOLAR DISORD, V19, P23, DOI 10.1111/bdi.12465
- Roberts G, 2016, PSYCHOL MED, V46, P2385, DOI 10.1017/S0033291716001161
- Sarrazin S, 2019, PSYCHOTHER PSYCHOSOM, V88, P171, DOI 10.1159/000498854
- Sarrazin S, 2014, JAMA PSYCHIAT, V71, P388, DOI 10.1001/jamapsychiatry.2013.4513
- Strakowski SM, 2012, BIPOLAR DISORD, V14, P313, DOI 10.1111/j.1399-5618.2012.01022.x
- Vederine FE, 2011, PROG NEURO-PSYCHOPH, V35, P1820, DOI 10.1016/j.pnpbp.2011.05.009
- Versace A, 2008, ARCH GEN PSYCHIAT, V65, P1041, DOI 10.1001/archpsyc.65.9.1041
- Wang F, 2008, BIOL PSYCHIAT, V64, P730, DOI 10.1016/j.biopsych.2008.06.001
- Wang F, 2008, BRIT J PSYCHIAT, V193, P126, DOI 10.1192/bjp.bp.107.048793
- Wise T, 2016, BIOL PSYCHIAT, V79, P293, DOI 10.1016/j.biopsych.2015.03.004
- Yang C, 2019, J PSYCHIATR NEUROSCI, V44, P32, DOI 10.1503/jpn.170221
- Yurgelun-Todd DA, 2007, BIPOLAR DISORD, V9, P504, DOI 10.1111/j.1399-5618.2007.00395.x
- Zanetti MV, 2009, EUR ARCH PSY CLIN N, V259, P316, DOI 10.1007/s00406-009-0002-8
- Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072